Synthesis and sst2 binding profiles of new (Tyr3)octreotate analogs

Journal of Peptide Science

Volumn 14, Issue 6, 2008, Pages 725-730

  Petrou, Christos ^a   Magafa, Vassiliki ^a   Nikolopoulou, Anastasia ^b   Pairas, George ^a   Nock, Berthold ^b   Maina, Theodosia ^b   Cordopatis, Paul ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

Tyra octreotate; AR4 2J cells; Binding affinity; Somatostatin analogs; sst2

Indexed keywords

CELL PROTEIN; OCTREOTIDE; OCTREOTIDE[1 ASPARTIC ACID]; OCTREOTIDE[1 NAPHTHYLALANINE]; OCTREOTIDE[1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXYLIC ACID]; OCTREOTIDE[3 PHENYLGLYCINE]; OCTREOTIDE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE] DERIVATIVE; OCTREOTIDE[3 TYROSINE] I 125; OCTREOTIDE[8 ASPARTIC ACID]; OCTREOTIDE[8 ASPARTYLASPARTIC ACID]; OCTREOTIDE[8 ASPARTYLLYSINE]; OCTREOTIDE[8 LYSINE]; OCTREOTIDE[9 SERINE]; OCTREOTIDE[ASPARAGINE DEXTRO 1 PHENYLGLYCINE 3 PHENYLGLYCINE]; OCTREOTIDE[ASPARAGINE DEXTRO 1 TYROSYLETHER]; OCTREOTIDE[ASPARAGINE]; OCTREOTIDE[BENZOTHIENYLALANINE]; OCTREOTIDE[DEXTRO 1 PHENYLGLYCINE 3 PHENYLGLYCINE]; OCTREOTIDE[DEXTRO 1 PHENYLGLYCINE]; OCTREOTIDE[DEXTRO 1 TYROSINE] DERIVATIVE; OCTREOTIDE[DEXTRO 1 TYROSYLETHER]; PROTEIN SST2; RADIOLIGAND; SOMATOSTATIN DERIVATIVE;

ACINAR CELL; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CONTROLLED STUDY; DRUG BINDING; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; IC 50; ISOTOPE LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; CELL LINE, TUMOR; PEPTIDES, CYCLIC; RATS; SOMATOSTATIN; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 47249129103     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.989     Document Type: Article

References (41)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77-79.
2. Koerker DJ, Harker LA, Goodner CJ. Effects of somatostatin on hemostasis in baboons. N. Engl. J. Med. 1975; 293: 476-479.
3. Gerich JE, Lovinger R, Grodsky GM. Inhibition by somatostatin of glucagon and insulin release from the perfused rat pancreas in response to arginine, isoproterenol and theophylline: evidence for a preferential effect on glucagon secretion. Endocrinology 1975; 96: 749-754.
4. Johansson C, Wisen O, Efendic S, Uvnas Wallensten K. Effects of graded doses of somatostatin on gallbladder emptying and pancreatic enzyme output after oral glucose in man. Digestion 1981; 22: 126-137.
5. Reichlin S. Somatostatin (Second of two parts). N. Engl. J. Med. 1983; 309: 1556-1563.
6. Epelbaumd. Somatostatin in the central nervous system: Physiology and pathological modifications. J. Prog. Neurobiol. 1986; 27: 63-100.
7. Epelbaum J, Dournaud P, Fodor M, Viollet C. The neurobiology of somatostatin. Crit. Rev. Neurobiol. 1994; 8: 25-44.
8. Lewin MJM. The somatostatin receptor in the GI tract. Annu. Rev. Physiol. 1992; 54: 455-468.
9. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogues. Chemotherapy 2001; 47(Suppl. 2): 30-39.
10. Pradayrol L, Jornvall H, Mutt V, Ribet A. N-terminally extended somatostatin: The primary structure of somatostatin-28. FEBS Lett. 1980; 109: 55-58.
11. Reisine T. Somatostatin. Cell. Mol. Neurobiol. 1995; 15: 597-614.
12. Meyerhof W. The elucidation of somatostatin receptor functions: A current view. Rev. Physiol. Bioch. P. 1996; 133: 55-108.
13. Patel YC. Somatostatin and its receptor family. Front. Neuroendocrinol. 1999; 20: 157-198.
14. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr. Rev. 1995; 16: 427-442.
15. Hofland LJ, Lamberts SWJ. Somatostatin receptor subtype expression in human tumors. Ann. Oncol. 2001; 12: S31-S36.
16. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 2001; 28: 836-846, Erratum in: Eur. J. Nucl. Med. 2001; 28: 1433.
17. Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumorhost interaction? Int. J. Cancer 1994; 56: 681-688.
18. Reubi JC, Schaer JC, Waser B, Mengod G. Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994; 54: 3455-3459.
19. Froidevaux S, Eberle AN. Somatostatin analogues and radiopeptides in cancer therapy. Biopolymers (Pept. Sci.) 2002; 66: 161-183.
20. Veber DF, Freidinger RM, Perlow DS. A potent cyclic hexapeptide analogue of somatostatin. Nature 1981; 292: 55-58.
21. Bauer W, Briner U, Doepfner W. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982; 31: 1133-1140.
22. Melacini G, Zhu Q, Goodman M. Multiconformational NMR analysis of sandostatin (octreotide): equilibrium between beta-sheet and partially helical structures. Biochemistry 1997; 36: 1233-1241.
23. Pohl E, Heine A, Sheldrick GM, Dauter Z, Wilson KS, Kallen J, Huber W, Pfaeffli PJ. Structure of Octreotide, a somatostatin analogue. Acta Crystallogr. 1995; D51: 48-59.
24. Wynants C, Tourwe D, Kazmierski W, Hruby VJ, Van Binst G. Conformation of two somatostatin analogues in aqueous solution. Study by NMR methods and circular dichroism. Eur. J. Biochem. 1989; 185: 371-381.
25. 3]octreotate derivatives in DMSO: Structure differentiation of peptide core due to chelate group attachment and biologically active conformation. Med. Chem. 2005; 1: 487-499.
26. 111In-labeled somatostatin analogue for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998; 58: 437-441.
27. Krenning EP, Kwekkeboom DJ, Pauels EK, Kvolls LK, Reubi JC. Somatostatin receptor scintigraphy. In Nuclear Medicine Annual, Freeman LM (ed.). Raven Press: New York, 1995; 1-50.
28. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, Bakker WH, Smith C, Pauwels S, Krenning EP. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin. Nucl. Med. 2002; 32: 133-140.
29. 99mTc-Demotate 1: First data in tumour patients-Results of a Pilot/Phase I study. Eur. J. Nucl. Med. Mol. Imaging 2003; 30: 1211-1219.
30. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: Synthesis, radiolabelling and in vitro validation. Life Sci. 1991; 49: 1583-1591.
31. 111In-DTPAD-Phe]-and [123 i_Tyr3]octreotide: The Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993; 20: 716-731.
32. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogue of octreotide for predictive imaging and targeted radiotherapy. Clin. Cancer Res. 2005; 11: 1136-1145.
33. Fields BG, Noble LR. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl-amino acids. Int. J. Pept. Protein Res. 1990; 35: 161-214.
34. Barlos K, Chatzi O, Gatos D, Stavropoulos G. 2-Chlorotrityl chloride resin: studies on anchoring of Fmoc-amino acids and peptide cleavage. Int. J. Pept. Protein Res. 1991; 37: 513-520.
35. Köning W, Geiger R. Eine neue methode zur synthese von peptiden: aktivierung der carboxylgruppe mit dicyclohexylcarbodiimid unter zusatz von 1-hydroxy-benzotriazolen. Chem. Ber. 1970; 103: 788-798.
36. Kaiser E, Colescott RL, Bossinger CD, Cook PI. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem. 1970; 34: 595-598.
37. Vojkovsky T. Detection of secondary amines on solid phase. Pept. Res. 1995; 8: 236-237.
38. Tam JP, Wu CR, Liu W, Zhang JW. Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications. J. Am. Chem. Soc. 1991; 113: 6657-6662.
39. Maruyama T, Ikeo T, Ueki M. A rapid and facile method for the preparation of peptide disulfides. Tetrahedron Lett. 1999; 40: 5031-5034.
40. 3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur. J. Nucl. Med. Mol. Imaging 2002; 29: 742-753.
41. Lowry OH, Rosebrough NJ, Farr AL, Randall J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 1951; 193: 265-275.